NOV 03, 2016 12:00 PM PDT

Use of QIAGEN® Clinical Insight (QCI™) Interpret to Elucidate Precision in Breast Cancer Targeted Therapy

C.E. CREDITS: P.A.C.E. CE | Florida CE
  • Manager, Advanced Genomics Integrated Solutions
      After completing in a B.S. in Biochemistry, Dr Deschênes obtained a Master in Pharmacology from University of Montréal, Canada focusing on the development of competitive antagonist for the Natriuretic Peptide Receptor B. She completed her Ph.D. in Biochemistry and Molecular Biology in 2008 at the Institute for Research in Immunology and Cancer (IRIC) in Montréal where she studied Breast Cancer by looking at the transcriptional regulation of estrogen receptor to the DNA through long-range regulation by estrogen. Dr Deschênes has been an author on numerous peer-reviewed articles and spoken on a variety of high-level panels, symposiums, and conference sessions.

      Dr. Deschênes joined QIAGEN in 2007 through Ingenuity Systems, now part of QIAGEN Bioinformatics and has since worked closely with customers and partner identifying insights in their NGS and expression analysis data as well helping the implementation of their clinical decision support software. She is a strong customer advocate thriving on partnering with customer to meet and exceed their needs. She recently obtained her Executive MBA on Market Strategy for a Next-Generation Sequencing Clinical Reporting Software from the Würzburg Universität, Germany while supporting the market entry of QIAGEN Clinical Insight Interpret.
    • Senior Scientist, Advanced Genomics Support; QIAGEN Bioinformatics
        Dilhan Weeraratne is a cancer genomics scientist invested in leveraging the explosion of genomics data to transform cancer treatment and patient outcome. Dilhan has over a decade of experience in cancer genomics and precision oncology both in academic and industry settings.

        Dilhan obtained his PhD in neuroscience/molecular biology from University of Vermont in 2007. Subsequently, he joined Harvard Medical School and Broad institute, MIT to do postdoctoral research in medulloblastoma genomics. His work was instrumental in defining the currently WHO accepted molecular subgroups of Medulloblastoma. Dilhan's work on genomic landscape of medulloblastoma was published in the journal "Nature". Following his postdoctoral work, Dilhan transitioned to biopharma and worked at leading diagnostics companies including Thermo Fisher and N-of-One working on clinical interpretation and annotation of biomarkers in solid and hematological tumors, clinical reporting and developing pharmacogenomics biomarker knowledgebases. Dilhan Joined QIAGEN in May of 2016.


      Breast cancer is a complex heterogeneous disease, with each subtype characterized by distinct clinical features and molecular alterations. The heterogeneity of breast cancer has presented massive challenges for identifying appropriate treatment for each patient. Advances in next-generation sequencing (NGS) have presented unique treatment opportunities beyond stratification of patients by hormone receptor and epidermal growth factor receptor status. QIAGEN® Clinical Insight (QCI™ Interpret) is a web-based application for the annotation, classification, and reporting of actionable variants from NGS data in clinical genomics laboratories.

      Learning Objectives: 

      • Understand how QCI Interpret identifies molecular alterations that have direct treatment implications for patients, based on five real world clinical cases from TCGA.
      • Discover how the richness of the QIAGEN Knowledge Base and the versatility of QCI Interpret contribute to  presenting treatment options for patients.

      Show Resources
      Loading Comments...